 |
11 Diseases |  |
1 Trial |
|
1 Trial |  |
98 News |  |
| «12 |
- | eritoran (E5564) / Eisai
Journal, IO Biomarker: Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance. (Pubmed Central) - Aug 3, 2019
The results demonstrate an antidepressant-like activity of ERI in Wistar rats exposed to CRS, which may be largely mediated by its ability to reduce neuroinflammation, increase BDNF, and restore GABA/glutamate balance in prefrontal cortex and hippocampus. Nonetheless, further studies are needed to characterize the mechanism of the antidepressant effect of ERI.
- | Esmocard (esmolol) / AOP Orphan Pharma, eritoran (E5564) / Eisai
Journal, IO Biomarker: β1 receptor blocker decreases the myocardial inflammation in the sepsis adult rats through inhibition of TLR4/NF-ΚB signaling pathway (Pubmed Central) - Jul 26, 2019
Nonetheless, further studies are needed to characterize the mechanism of the antidepressant effect of ERI. β1 receptor blocker esmolol may inhibit myocardial inflammatory response in sepsis adult rats through TLR4/NF-ΚB signaling pathway, thereby alleviating sepsis-induced myocardial injury.
- || eritoran (E5564) / Eisai
US Air Force Selects L3Harris Technologies to Develop Airborne HF Replacement Radio for AN/ARC-190 https://t.co/KMxPe5564S (Twitter) - Jul 3, 2019
- | eritoran (E5564) / Eisai
Journal: TLR4-directed Molecular Strategies Targeting Skin Photodamage and Carcinogenesis. (Pubmed Central) - Mar 27, 2019
β1 receptor blocker esmolol may inhibit myocardial inflammatory response in sepsis adult rats through TLR4/NF-ΚB signaling pathway, thereby alleviating sepsis-induced myocardial injury. Future research should explore the skin photoprotective and photochemopreventive efficacy of topical TLR4 antagonism if employed in conjunction with other molecular strategies including sunscreens.
- | NN1213 / Novo Nordisk, eritoran (E5564) / Eisai
Trial termination: Eritoran1: The Role of TLR4 on Lipid-induced Insulin Resistance (clinicaltrials.gov) - Sep 18, 2018
P2, N=16, Terminated, Sponsor: The University of Texas Health Science Center at San Antonio
Future research should explore the skin photoprotective and photochemopreventive efficacy of topical TLR4 antagonism if employed in conjunction with other molecular strategies including sunscreens. Suspended --> Terminated
- | eritoran (E5564) / Eisai
Enrollment change, Trial termination: Eritoran2: The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects (clinicaltrials.gov) - Sep 18, 2018
P2, N=15, Terminated, Sponsor: Nicolas Musi
Suspended --> Terminated N=60 --> 15 | Suspended --> Terminated; Study drug expired
- | Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Aug 20, 2018
P4, N=6800, Recruiting, Sponsor: MJM Bonten
N=60 --> 15 | Suspended --> Terminated; Study drug expired N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016
- | eritoran (E5564) / Eisai
Trial suspension, IO biomarker: Eritoran1: The Role of TLR4 on Lipid-induced Insulin Resistance (clinicaltrials.gov) - Sep 11, 2017
P2, N=20, Suspended, Sponsor: The University of Texas Health Science Center at San Antonio
N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016 Recruiting --> Suspended
- | eritoran (E5564) / Eisai
Trial suspension, IO biomarker: Eritoran2: The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects (clinicaltrials.gov) - Sep 11, 2017
P2, N=60, Suspended, Sponsor: Nicolas Musi
Recruiting --> Suspended Recruiting --> Suspended
- | New P4 trial: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Apr 13, 2016
P4, N=4000, Recruiting, Sponsor: UMC Utrecht
- eritoran (E5564) / Eisai
Enrollment open, IO biomarker: Eritoran1: The Role of TLR4 on Lipid-induced Insulin Resistance (clinicaltrials.gov) - Jan 21, 2015
P2, N=20, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Suspended Not yet recruiting --> Recruiting
- eritoran (E5564) / Eisai
Enrollment open, IO biomarker: Eritoran2: The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects (clinicaltrials.gov) - Jan 18, 2015
P2, N=60, Recruiting, Sponsor: Nicolas Musi, MD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- eritoran (E5564) / Eisai
New P2 trial, IO biomarker: Eritoran1: The Role of TLR4 on Lipid-induced Insulin Resistance (clinicaltrials.gov) - Dec 22, 2014
P2, N=20, Not yet recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- | eritoran (E5564) / Eisai
New P2 trial, IO biomarker: Eritoran2: The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects (clinicaltrials.gov) - Oct 17, 2014
P2, N=60, Not yet recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- ||||||| eritoran (E5564) / Eisai
Trial completion: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis (clinicaltrials.gov) - Jan 1, 2013
P3, N=2000, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed